SM
RGLS

Sabby Management’s Regulus Therapeutics RGLS Stock Holding History

Sabby Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5
Closed -$398K – 323
2016
Q1 		$398K Buy
5
+1
+25% +$796 0.02% 228
2015
Q4 		$436K Buy
+4
New +$4.01K 0.02% 244

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Sabby Management's RGLS Position: Q3 2016 in Review

Sabby Management sold out of Regulus Therapeutics (RGLS) in Q3 2016, closing a stake of 410 shares — an estimated $169K sold.

Sabby Management first reported a position in RGLS in Q4 2014 and held it in 7 quarters. The position peaked at $5.65M in Q4 2014. 83 funds tracked by Wall St. Rank hold RGLS as of Q3 2016.

  • Sabby Management reported no remaining Regulus Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Sabby Management sold 410 Regulus Therapeutics shares in Q3 2016, an estimated $169K.
  • Sabby Management first reported a position in Regulus Therapeutics in Q4 2014 and held it in 7 quarters.
  • Sabby Management's Regulus Therapeutics position peaked at $5.65M in Q4 2014.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.